MX2022003585A - Metodos para tratar hiperfenilalaninemia. - Google Patents

Metodos para tratar hiperfenilalaninemia.

Info

Publication number
MX2022003585A
MX2022003585A MX2022003585A MX2022003585A MX2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A MX 2022003585 A MX2022003585 A MX 2022003585A
Authority
MX
Mexico
Prior art keywords
methods
hyperphenylalaninemia
treat
sepiapterin
administration
Prior art date
Application number
MX2022003585A
Other languages
English (en)
Spanish (es)
Inventor
Niel Smith
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72827023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022003585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2022003585A publication Critical patent/MX2022003585A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2022003585A 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia. MX2022003585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
MX2022003585A true MX2022003585A (es) 2022-04-19

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003585A MX2022003585A (es) 2019-09-25 2020-09-25 Metodos para tratar hiperfenilalaninemia.

Country Status (23)

Country Link
US (1) US20220362249A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034122B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220070477A (cg-RX-API-DMAC7.html)
CN (1) CN114650825A (cg-RX-API-DMAC7.html)
AU (1) AU2020353676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003719A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150003A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034122T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041002T3 (cg-RX-API-DMAC7.html)
FI (1) FI4034122T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251268T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073483T2 (cg-RX-API-DMAC7.html)
IL (1) IL291565B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20220042A1 (cg-RX-API-DMAC7.html)
LT (1) LT4034122T (cg-RX-API-DMAC7.html)
MX (1) MX2022003585A (cg-RX-API-DMAC7.html)
PL (1) PL4034122T3 (cg-RX-API-DMAC7.html)
PT (1) PT4034122T (cg-RX-API-DMAC7.html)
RS (1) RS67295B1 (cg-RX-API-DMAC7.html)
SI (1) SI4034122T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500493T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩

Also Published As

Publication number Publication date
ES3041002T3 (en) 2025-11-06
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
BR112022003719A2 (pt) 2022-05-31
DK4034122T3 (da) 2025-09-15
EP4034122A1 (en) 2022-08-03
FI4034122T3 (fi) 2025-10-08
RS67295B1 (sr) 2025-11-28
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
SMT202500493T1 (it) 2026-01-12
HUE073483T2 (hu) 2026-01-28
AU2020353676B2 (en) 2026-04-30
JP2025111476A (ja) 2025-07-30
IL291565B1 (en) 2026-04-01
SI4034122T1 (sl) 2025-12-31
KR20220070477A (ko) 2022-05-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
EP4034122B1 (en) 2025-08-13
CA3150003A1 (en) 2021-04-01
PL4034122T3 (pl) 2026-01-26
IL291565A (en) 2022-05-01
AU2020353676A1 (en) 2022-04-14
LT4034122T (lt) 2025-11-10
JP7661315B2 (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
CL2019000485A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
EA201890006A1 (ru) Применение экзосом для лечения болезни
MX387115B (es) Métodos para tratar la influenza.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
AR093705A1 (es) Depsipeptido y sus usos
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
EA201792214A1 (ru) Соединения замещенного хиназолина
BR112022003719A2 (pt) Métodos para o tratamento de hiperfenilalaninemia
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
MX2018003023A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
ECSP22016180A (es) Proteínas de fusión terapéuticas
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
EA201891342A1 (ru) Изоиндольные соединения
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CY1124851T1 (el) Νεες ενωσεις